Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oxygenta Pharmaceutical's Enterprise Value is ₹2,970 Mil.
Oxygenta Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil. Therefore, Oxygenta Pharmaceutical's EV-to-FCF for today is .
The historical rank and industry rank for Oxygenta Pharmaceutical's EV-to-FCF or its related term are showing as below:
BOM:524636'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.31 Med: 0 Max: 0
Current: -7.31
BOM:524636's EV-to-FCF is ranked worse than 100% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.66
vs BOM:524636: -7.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oxygenta Pharmaceutical's PE Ratio (TTM) for today is calculated as:
Oxygenta Pharmaceutical's share price for today is ₹51.25.
Oxygenta Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-3.670.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Oxygenta Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxygenta Pharmaceutical EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Oxygenta Pharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Oxygenta Pharmaceutical's EV-to-FCF falls into.
Oxygenta Pharmaceutical's current Enterprise Value is ₹2,970 Mil.
Oxygenta Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Oxygenta Pharmaceutical (BOM:524636) Overvalued in 2026?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical stock appears to be undervalued.
The current stock price of ₹51.25 is trading 39.2% below its estimated GF Value™ of ₹84.23.
GuruFocus considers Oxygenta Pharmaceutical to be Possible Value Trap.
Key valuation signals for BOM:524636:
EV-to-FCF:
GF Value™: ₹84.23 vs. price of ₹51.25 (39.2% below fair value)
No single metric tells the full story. See the BOM:524636 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxygenta Pharmaceutical Ltd is a pharmaceutical company. It is engaged in the business activity of is engaged in manufacturing and selling of Pharmaceutical, medical, and veterinary preparations. The Company has one reportable segment, which is Pharmaceutical. The group carries out its business operations within India.
42GF Score
Get the complete analysis for BOM:524636
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524636 has been successfully added to your 
